Financial Advocates Investment Management’s Nektar Therapeutics NKTR Stock Holding History

Financial Advocates Investment Management’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-703	Closed	-$6.07K	–	726
2023 Q2	$6.07K	Sell	703 -126	-15%	-$1.34K	﹤0.01%	694
2023 Q1	$8.74K	Hold	829	–	–	﹤0.01%	737
2022 Q4	$28.1K	Buy	+829	New	+$40.1K	﹤0.01%	741
2022 Q3	–	Sell	-829	Closed	-$47K	–	803
2022 Q2	$47K	Sell	829 -1,117	-57%	-$70.5K	﹤0.01%	668
2022 Q1	$157K	Sell	1,946 -5,416	-74%	-$802K	0.01%	697
2021 Q4	$1.76M	Buy	7,362 +5,894	+401%	+$1.28M	0.11%	220
2021 Q3	$409K	Buy	1,468 +311	+27%	+$74.8K	0.03%	520
2021 Q2	$328K	Buy	+1,157	New	+$320K	0.02%	594
2020 Q1	–	Sell	-945	Closed	-$538K	–	525
2019 Q4	$538K	Buy	945 +151	+19%	+$43.8K	0.06%	301
2019 Q3	$217K	Buy	+794	New	+$291K	0.02%	445

Other funds holding NKTR

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

MAM

Monaco Asset Management Monaco $1.26B AUM 60.23% 1-Year Est. Return

Financial Advocates Investment Management's NKTR Position: Q3 2023 in Review

Financial Advocates Investment Management sold out of Nektar Therapeutics (NKTR) in Q3 2023, closing a stake of 703 shares — an estimated $6.07K sold.

Financial Advocates Investment Management first reported a position in NKTR in Q3 2019 and held it in 10 quarters. The position peaked at $1.76M in Q4 2021. 138 funds tracked by Wall St. Rank hold NKTR as of Q3 2023.

Financial Advocates Investment Management reported no remaining Nektar Therapeutics position as of Q3 2023 after selling out during the quarter.
Financial Advocates Investment Management sold 703 Nektar Therapeutics shares in Q3 2023, an estimated $6.07K.
Financial Advocates Investment Management first reported a position in Nektar Therapeutics in Q3 2019 and held it in 10 quarters.
Financial Advocates Investment Management's Nektar Therapeutics position peaked at $1.76M in Q4 2021.
138 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q3 2023.

Based on Financial Advocates Investment Management's 13F filing for Q3 2023, filed 27 Oct 2023.